NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has purchased next-generation sequencing technology firm GnuBio for an undisclosed price in order to give it capabilities in the NGS space, especially for clinical applications, Bio-Rad said this week.

Cambridge, Mass.-based GnuBio is developing a droplet-based sequencing platform that uses "picoinjector" technology developed in co-founder David Weitz’s physics laboratory at Harvard University.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.